AR128310A1 - Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3,2:5,6]pirido[2,3-b][1,4]oxazepina - Google Patents
Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3,2:5,6]pirido[2,3-b][1,4]oxazepinaInfo
- Publication number
- AR128310A1 AR128310A1 ARP230100132A ARP230100132A AR128310A1 AR 128310 A1 AR128310 A1 AR 128310A1 AR P230100132 A ARP230100132 A AR P230100132A AR P230100132 A ARP230100132 A AR P230100132A AR 128310 A1 AR128310 A1 AR 128310A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- compound
- pyrido
- pharmaceutically acceptable
- acceptable salt
- Prior art date
Links
- 239000012664 BCL-2-inhibitor Substances 0.000 title 1
- 229940123711 Bcl2 inhibitor Drugs 0.000 title 1
- YIOBXTCJTWWMJA-UHFFFAOYSA-N pyrido[2,3-b][1,4]oxazepine Chemical compound O1C=CC=NC2=CC=CN=C12 YIOBXTCJTWWMJA-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 6
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 abstract 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 2
- 125000003566 oxetanyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 abstract 1
- 125000005083 alkoxyalkoxy group Chemical group 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000000532 dioxanyl group Chemical group 0.000 abstract 1
- 125000002757 morpholinyl group Chemical group 0.000 abstract 1
- 125000003386 piperidinyl group Chemical group 0.000 abstract 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 abstract 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263267018P | 2022-01-21 | 2022-01-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR128310A1 true AR128310A1 (es) | 2024-04-17 |
Family
ID=85382827
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP230100132A AR128310A1 (es) | 2022-01-21 | 2023-01-20 | Inhibidores de bcl-2 de 1,3,4,7-tetrahidro-2h-pirrolo[3,2:5,6]pirido[2,3-b][1,4]oxazepina |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11964990B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4466273A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7714811B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240136972A (cg-RX-API-DMAC7.html) |
| CN (1) | CN119053610A (cg-RX-API-DMAC7.html) |
| AR (1) | AR128310A1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2023210279A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3242074A1 (cg-RX-API-DMAC7.html) |
| CO (1) | CO2024009334A2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL312709A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2024008840A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340210A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023141536A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202340210A (zh) * | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 |
| CN117820134A (zh) * | 2024-01-10 | 2024-04-05 | 山东盛安贝新材料有限公司南京分公司 | 一种顺式-3-甲氧基环丁胺盐酸盐的制备方法 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020002032A (es) | 2017-08-23 | 2020-09-17 | Guangzhou Lupeng Pharmaceutical Company Ltd | Inhibidores de bcl-2. |
| US11903950B2 (en) | 2018-08-22 | 2024-02-20 | Newave Pharmaceutical Inc. | BCL-2 inhibitors |
| WO2020140005A2 (en) | 2018-12-29 | 2020-07-02 | Newave Pharmaceutical Inc. | Bcl-2 inhibitors |
| WO2021066873A1 (en) | 2019-10-03 | 2021-04-08 | Newave Pharmaceutical Inc. | Condensed heterocycles as bcl-2 inhibitors |
| WO2021083135A1 (en) | 2019-10-28 | 2021-05-06 | Beigene, Ltd. | Bcl-2 INHIBITORS |
| WO2021133817A1 (en) | 2019-12-27 | 2021-07-01 | Guangzhou Lupeng Pharmaceutical Company Ltd. | 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases |
| MX2022010410A (es) | 2020-02-24 | 2022-12-07 | Guangzhou Lupeng Pharmaceutical Company Ltd | Dispersiones de sólidos con extrusión por termofusión que contienen un inhibidor bcl2. |
| TW202340210A (zh) * | 2022-01-21 | 2023-10-16 | 美商艾伯維有限公司 | 1,3,4,7-四氫-2H-吡咯并[3',2':5,6]吡啶并[2,3-b][1,4]氮呯Bcl-2抑制劑 |
-
2023
- 2023-01-19 TW TW112102814A patent/TW202340210A/zh unknown
- 2023-01-19 US US18/156,987 patent/US11964990B2/en active Active
- 2023-01-20 KR KR1020247023725A patent/KR20240136972A/ko active Pending
- 2023-01-20 AR ARP230100132A patent/AR128310A1/es unknown
- 2023-01-20 WO PCT/US2023/060944 patent/WO2023141536A1/en not_active Ceased
- 2023-01-20 JP JP2024540933A patent/JP7714811B2/ja active Active
- 2023-01-20 CN CN202380016422.5A patent/CN119053610A/zh active Pending
- 2023-01-20 AU AU2023210279A patent/AU2023210279A1/en active Pending
- 2023-01-20 IL IL312709A patent/IL312709A/en unknown
- 2023-01-20 EP EP23707582.5A patent/EP4466273A1/en active Pending
- 2023-01-20 MX MX2024008840A patent/MX2024008840A/es unknown
- 2023-01-20 CA CA3242074A patent/CA3242074A1/en active Pending
-
2024
- 2024-03-05 US US18/595,898 patent/US20250066388A1/en not_active Abandoned
- 2024-07-15 CO CONC2024/0009334A patent/CO2024009334A2/es unknown
-
2025
- 2025-07-02 US US19/258,642 patent/US20260028356A1/en active Pending
- 2025-07-15 JP JP2025118767A patent/JP2025160251A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2023210279A1 (en) | 2024-05-23 |
| JP2025504382A (ja) | 2025-02-12 |
| IL312709A (en) | 2024-07-01 |
| CA3242074A1 (en) | 2023-07-27 |
| CO2024009334A2 (es) | 2024-07-18 |
| TW202340210A (zh) | 2023-10-16 |
| US20230234971A1 (en) | 2023-07-27 |
| KR20240136972A (ko) | 2024-09-19 |
| US20250066388A1 (en) | 2025-02-27 |
| MX2024008840A (es) | 2024-07-25 |
| EP4466273A1 (en) | 2024-11-27 |
| JP7714811B2 (ja) | 2025-07-29 |
| WO2023141536A1 (en) | 2023-07-27 |
| US11964990B2 (en) | 2024-04-23 |
| US20260028356A1 (en) | 2026-01-29 |
| CN119053610A (zh) | 2024-11-29 |
| JP2025160251A (ja) | 2025-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2412192C2 (ru) | Сульфонамидтиазолпиридиновые производные как активаторы глюкокиназы, пригодные для лечения диабета типа 2 | |
| RU2009127095A (ru) | Новые оксадиазольные соединения | |
| AR077908A1 (es) | Compuestos de oxadiazol como moduladores de s1p | |
| PE20212304A1 (es) | Inhibidores de il-17a imidazo[1,2-b]piridazin-2-il | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR060159A2 (es) | Combinaciones de compuestos derivados de tropano utiles en terapia | |
| HRP20030450B1 (en) | Isoindolin-1-one glucokinase activators | |
| AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
| CO6251287A2 (es) | Derivados de oxadiazol y su uso como potenciadores de los receptores metabotropicos de glutamato -842 | |
| NO20050841L (no) | Pyrazolo [3,4-B] pyridinforbindelser, og deres anvendelse som fosfodiesteraseinhibitorer | |
| JP2017526636A5 (cg-RX-API-DMAC7.html) | ||
| RU2016146365A (ru) | Новые дигидрохинолизиноны для лечения и профилактики заражения вирусом гепатита b | |
| AR077463A1 (es) | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias | |
| ES2625256T3 (es) | Compuestos de tetrahidroisoquinolina sustituidos como inhibidores del factor XIA | |
| BR0309398A (pt) | Composto ou um seu sal, hidrato, solvato, forma cristalina, diastereÈmero, prodroga farmaceuticamente aceitável, ou misturas deles, composição farmacêutica, e, métodos para tratar uma condição envolvida com a cinase em um mamìfero, para tratar câncer, e para identificar uma cinase | |
| CO5700757A2 (es) | Derivados de (3-oxo-3,4-dihidro-quinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad | |
| JP2016505619A5 (cg-RX-API-DMAC7.html) | ||
| ES2529691T3 (es) | Derivados de 3-amino-imidazo [1,2-A] piridina como inhibidores de SGLT | |
| AR079783A1 (es) | Derivados de tienopirrol, una composicion farmaceutica que los comprende y su uso en el tratamiento de enfermedades mediadas por la inhibicion de las proteinas quinasas | |
| AR096149A1 (es) | Macrociclos como inhibidores de quinasa | |
| FI3466934T3 (fi) | Sulfonamidiyhdisteitä tai niiden suola ribonukleotidireduktaasin inhibiittoreina syövän hoitamiseksi | |
| AR047891A1 (es) | Derivados de heteroaril fenilurea | |
| CO6210701A2 (es) | Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico | |
| PE20120356A1 (es) | Compuestos para el tratamiento de trastornos metabolicos | |
| RU2007122485A (ru) | Ингибиторы киназы |